’s shares jumped up to 10% intraday after Q2FY26 net profit rose 29.6% YoY to ₹258.3 crore, with a net margin of 15.7%, reflecting robust operating momentum across India and Cayman businesses. Consolidated operating revenue grew 20.3% YoY to ₹1,644 crore and 9.1% QoQ, while EBITDA rose 28.3% YoY to ₹426.5 crore with margins improving to 25.9%. Growth drivers India operations delivered ₹1,235 crore revenue, up 8.8% YoY, aided by stronger footfalls, better payor mix, and clinics outreach, alongside procedural depth including >1,000 robotic surgeries and new services like BMT in Jaipur. Cayman Islands posted ₹432 crore revenue, up 78.1% YoY, with both hospital and insurance businesses scaling and creating ecosystem synergies that support sustained growth. Financial health Net debt-to-equity stood at 0.06; net borrowings were ₹247 crore as of September 30, 2025, underscoring balance-sheet strength for expansion and technology upgrades. Management flagged highest-ever revenue and profitability at both India and group levels, highlighting operating leverage and improving case mix. What to watch Capacity additions, international patient mix, and integrated care/insurance scale-up to sustain growth and margins through FY26. Continued productivity gains from robotics, minimally invasive programs, and high-end diagnostics to reinforce ARPOB and throughput. No Recommendations Source: The Economic Times

#FundamentalViews#EquityResearch

466 likes·76 comments